Enzyme inhibitors and viral infection therapy
AssigneeUniversity of Southern California
InventorsPinghui FENG, Chao ZHANG, Jun ZHAO, Biancha ESPINOSA, Chao QIN, Ali SAVAS, Youliang RAO, Ting-Yu WANG
Life of this patent
Estimating the term…
Abstract
The invention relates to antiviral compounds, compositions comprising antiviral compounds, and methods of use. In particular, the antiviral compounds are cytidine triphosphate synthetase 1 (CTPS1) inhibitors that are effective in treating and/or preventing viral infection and in particular, SARS-CoV-2 infection and/or COVID-19 disease.
Claims20
A compound of Formula I:
- wherein,
- G is
- or S;
- R1 is —NH(C═O)CH2X wherein X is a leaving group;
- R2 is —(C═O)NRaR3 or —NRa(C═O)R3, wherein Ra is H or —(C1-C6)alkyl;
- R3 is —(C1-C6)alkyl, —(C3-C6)cycloalkyl, phenyl-R4, or 5- or 6-membered heteroaryl;
- and
- R4 is —O(C1-C6)alkyl, —(C1-C6)alkyl, halo, or H;
- wherein R1 is in the beta-position relative to R2, and each (C1-C6)alkyl moiety is independently saturated or unsaturated and optionally interrupted by a heteroatom.
A method of treating a human subject identified as having or suspected of having COVID-19, the method comprising administering to the subject an effective amount of a cytidine triphosphate synthetase 1 (CTPS1) inhibitor effective to reduce interferon regulatory factor 3 (IRF3) deamidation, thereby treating the subject.
Dependencies are inferred from the claim text.